Advantage Investment Management’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Advantage Investment Management’s Portfolio PJP Stock Details PJP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-764	Closed	-$48K	–	1017
2018 Q1	$48K	Hold	764	–	–	0.02%	387
2017 Q4	$49K	Hold	764	–	–	0.02%	401
2017 Q3	$50K	Hold	764	–	–	0.02%	392
2017 Q2	$48K	Hold	764	–	–	0.02%	381
2017 Q1	$45K	Hold	764	–	–	0.02%	363
2016 Q4	$43K	Hold	764	–	–	0.02%	359
2016 Q3	$47K	Hold	764	–	–	0.02%	339
2016 Q2	$48K	Hold	764	–	–	0.02%	350
2016 Q1	$46K	Buy	+764	New	+$46.7K	0.02%	343

Other funds holding PJP

PAM

Peak Asset Management Louisville, Colorado $680M AUM 22.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Advantage Investment Management's PJP Position: Q2 2018 in Review

Advantage Investment Management sold out of Invesco Pharmaceuticals ETF (PJP) in Q2 2018, closing a stake of 764 shares — an estimated $48K sold.

Advantage Investment Management first reported a position in PJP in Q1 2016 and held it in 9 quarters. The position peaked at $50K in Q3 2017. 85 funds tracked by Wall St. Rank hold PJP as of Q2 2018.

Advantage Investment Management reported no remaining Invesco Pharmaceuticals ETF position as of Q2 2018 after selling out during the quarter.
Advantage Investment Management sold 764 Invesco Pharmaceuticals ETF shares in Q2 2018, an estimated $48K.
Advantage Investment Management first reported a position in Invesco Pharmaceuticals ETF in Q1 2016 and held it in 9 quarters.
Advantage Investment Management's Invesco Pharmaceuticals ETF position peaked at $50K in Q3 2017.
85 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q2 2018.

Based on Advantage Investment Management's 13F filing for Q2 2018, filed 13 Aug 2018.